MCID: PRS008
MIFTS: 28

Prostate Small Cell Carcinoma

Categories: Cancer diseases, Reproductive diseases, Respiratory diseases

Aliases & Classifications for Prostate Small Cell Carcinoma

MalaCards integrated aliases for Prostate Small Cell Carcinoma:

Name: Prostate Small Cell Carcinoma 12 14
Small Cell Carcinoma of Prostate 12 69
Prostate Oat Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7141
NCIt 47 C6766
SNOMED-CT 64 396198006
UMLS 69 C1300585

Summaries for Prostate Small Cell Carcinoma

MalaCards based summary : Prostate Small Cell Carcinoma, also known as small cell carcinoma of prostate, is related to small cell carcinoma and prostatitis. An important gene associated with Prostate Small Cell Carcinoma is SV2B (Synaptic Vesicle Glycoprotein 2B). The drugs Zoledronic acid and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and bone, and related phenotypes are Increased number of cells in monopolar arrest with EMD534085 (a Kinesin-5 inhibitor) and taste/olfaction

Related Diseases for Prostate Small Cell Carcinoma

Diseases related to Prostate Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)
id Related Disease Score Top Affiliating Genes
1 small cell carcinoma 10.4
2 prostatitis 10.3
3 adenocarcinoma 9.9
4 prostate adenocarcinoma 9.8
5 hole retinal cyst 9.7 ENO2 KLK3
6 sphenoid sinus squamous cell carcinoma 9.7 ENO2 KLK3
7 pancreatic agenesis 9.7 ENO2 KLK3
8 urethral villous adenoma 9.7 ENO2 KLK3
9 caroli disease 9.6 ASCL1 ENO2
10 pheochromocytoma 9.5 ASCL1 ENO2
11 brown-vialetto-van laere syndrome 9.5 ENO2 KLK3
12 leprosy 6 9.4 ASCL1 ENO2
13 brachyolmia 9.2 ASCL1 ENO2 KLK3
14 endocrine gland cancer 9.2 ASCL1 ENO2
15 neuroblastoma 8.9 ASCL1 AURKA ENO2
16 langerhans cell sarcoma 8.1 ASCL1 AURKA ENO2 KLK3 SV2B

Graphical network of the top 20 diseases related to Prostate Small Cell Carcinoma:



Diseases related to Prostate Small Cell Carcinoma

Symptoms & Phenotypes for Prostate Small Cell Carcinoma

GenomeRNAi Phenotypes related to Prostate Small Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased number of cells in monopolar arrest with EMD534085 (a Kinesin-5 inhibitor) GR00198-A-1 8.62 ASCL1 AURKA

MGI Mouse Phenotypes related to Prostate Small Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 taste/olfaction MP:0005394 8.62 ASCL1 ENO2

Drugs & Therapeutics for Prostate Small Cell Carcinoma

Drugs for Prostate Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 3 118072-93-8 68740
2
Dalteparin Approved Phase 3 9005-49-6
3
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
6
Morphine Approved, Investigational Phase 3 57-27-2 5288826
7
Gemcitabine Approved Phase 3,Phase 1 95058-81-4 60750
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
10
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
14 Bone Density Conservation Agents Phase 3
15 Calcium, Dietary Phase 3
16 Diphosphonates Phase 3
17 Ergocalciferols Phase 3
18 Micronutrients Phase 3
19 Radiopharmaceuticals Phase 3
20 Trace Elements Phase 3
21 Vitamins Phase 3
22 Liver Extracts Phase 3,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Anticoagulants Phase 3
25 calcium heparin Phase 3
26 Fibrinolytic Agents Phase 3
27 Heparin, Low-Molecular-Weight Phase 3
28 Adjuvants, Anesthesia Phase 3
29 Analgesics Phase 3
30 Analgesics, Opioid Phase 3
31 Anesthetics Phase 3
32 Anesthetics, General Phase 3
33 Anesthetics, Intravenous Phase 3
34 Central Nervous System Depressants Phase 3
35 Narcotics Phase 3
36 Peripheral Nervous System Agents Phase 3,Phase 2
37 Epoetin alfa Phase 3 113427-24-0
38 Hematinics Phase 3,Phase 2
39 Antibodies Phase 3,Phase 1,Phase 2
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 3,Phase 1
42 Antimetabolites, Antineoplastic Phase 3,Phase 1
43 Antiviral Agents Phase 3,Phase 1
44 Immunoglobulins Phase 3,Phase 1,Phase 2
45 Mitogens Phase 3,Phase 1
46 Antimitotic Agents Phase 3,Phase 2,Phase 1
47 Angiogenesis Inhibitors Phase 3
48 Angiogenesis Modulating Agents Phase 3
49 Antibodies, Monoclonal Phase 3,Phase 2
50 Endothelial Growth Factors Phase 3

Interventional clinical trials:

(show top 50) (show all 68)

id Name Status NCT ID Phase Drugs
1 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3 zoledronic acid;Sm-153
2 Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer Completed NCT00003674 Phase 3 dalteparin;standard therapy
3 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Completed NCT00003884 Phase 3 zoledronic acid
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
6 The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
7 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
8 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
9 LBH Phase II in Small Cell Lung Cancer (SCLC) Completed NCT01222936 Phase 2 LBH581
10 Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors Completed NCT00078845 Phase 2 Amifostine
11 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies Completed NCT00940225 Phase 2 XL184;Placebo;XL184;XL184
12 Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting NCT02893917 Phase 2 Cediranib;Olaparib
13 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
14 Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting NCT03263650 Phase 2 Cabazitaxel;Carboplatin;Prednisone 5Mg;Olaparib
15 Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers Recruiting NCT02141490 Phase 2 Ferumoxytol
16 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03150810 Phase 1, Phase 2 BGB-290;Temozolomide;BGB-290;Temozolomide
17 A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer Active, not recruiting NCT01799278 Phase 2 MLN8237
18 Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Withdrawn NCT00769990 Phase 1, Phase 2
19 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2 Ipilimumab
20 Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Withdrawn NCT00824811 Phase 2 Cyclosporine Eye Drops (Restasis);Lubricant Eye Drops (Refresh Endura™);Fluorometholone Eye Drops (FML Forte®)
21 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
22 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
23 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
24 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
25 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
26 Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors Completed NCT00620295 Phase 1 bortezomib;gemcitabine hydrochloride
27 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
28 Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed NCT01286987 Phase 1 Talazoparib
29 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
30 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
31 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
32 Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors Completed NCT02262455 Phase 1 STM 434;Liposomal doxorubicin
33 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Recruiting NCT01587703 Phase 1 GSK525762
34 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting NCT03076372 Phase 1 MM-310
35 Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Recruiting NCT02223052 Phase 1 CC-486;Vidaza
36 sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer Recruiting NCT02767921 Phase 1
37 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Recruiting NCT02391480 Phase 1 ABBV-075;Venetoclax
38 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma Active, not recruiting NCT01703481 Phase 1 JNJ-42756493: Part 1;JNJ-42756493: Part 2;JNJ-42756493: Part 3;JNJ-42756493: Part 4
39 A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies Suspended NCT01604863 Phase 1 HGS1036 + Paclitaxel + Carboplatin;HGS1036 + Cisplatin + Etoposide;HGS1036 + Docetaxel
40 Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Withdrawn NCT02567396 Phase 1 Talazoparib
41 Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer Unknown status NCT00303914
42 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
43 Tumor Bank for Tissue Samples Unknown status NCT01789229
44 Tumor Bank for Blood Samples Unknown status NCT01763125
45 Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer Completed NCT00900835
46 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
47 Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer Completed NCT00003329
48 Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors Completed NCT00433602
49 Psychosocial Adjustment After Radiation Therapy in Patients With Cancer Completed NCT00905086
50 Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients Completed NCT01434342 Nicotine Replacement Patch

Search NIH Clinical Center for Prostate Small Cell Carcinoma

Genetic Tests for Prostate Small Cell Carcinoma

Anatomical Context for Prostate Small Cell Carcinoma

MalaCards organs/tissues related to Prostate Small Cell Carcinoma:

39
Prostate, Lung, Bone, Kidney, Breast, Liver, Lymph Node

Publications for Prostate Small Cell Carcinoma

Articles related to Prostate Small Cell Carcinoma:

(show all 19)
id Title Authors Year
1
Solitary Spinal Epidural Metastasis from Prostatic Small Cell Carcinoma. ( 27413569 )
2016
2
Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. ( 25656929 )
2015
3
Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. ( 24777847 )
2015
4
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. ( 26246306 )
2015
5
Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. ( 23850495 )
2013
6
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. ( 22389383 )
2012
7
Re: PC3 is a cell line characteristic of prostatic small cell carcinoma. ( 22682868 )
2012
8
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. ( 21499238 )
2011
9
PC3 is a cell line characteristic of prostatic small cell carcinoma. ( 21432867 )
2011
10
ERG gene rearrangements are common in prostatic small cell carcinomas. ( 21336263 )
2011
11
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. ( 18835619 )
2009
12
[Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature]. ( 19947569 )
2009
13
Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. ( 18247403 )
2008
14
Prostate small cell carcinoma and skin metastases: a rare entity. ( 18408396 )
2008
15
Submandibular area metastasis from prostate small cell carcinoma with neuroendocrine differentiation. ( 17912103 )
2007
16
Establishment of a prostatic small-cell carcinoma cell line (SO-MI). ( 12772193 )
2003
17
Brain metastasis from prostate small cell carcinoma: not to be neglected. ( 12463494 )
2002
18
[A case of prostatic small cell carcinoma]. ( 10934615 )
2000
19
WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. ( 11118033 )
2000

Variations for Prostate Small Cell Carcinoma

Cosmic variations for Prostate Small Cell Carcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10889 TP53 prostate,NS,carcinoma,small cell carcinoma c.536A>G p.H179R 11
2 COSM938 RB1 prostate,NS,carcinoma,small cell carcinoma c.967G>T p.E323* 11
3 COSM3738526 FOXA1 prostate,NS,carcinoma,small cell carcinoma c.655C>A p.R219S 11

Expression for Prostate Small Cell Carcinoma

Search GEO for disease gene expression data for Prostate Small Cell Carcinoma.

Pathways for Prostate Small Cell Carcinoma

GO Terms for Prostate Small Cell Carcinoma

Sources for Prostate Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....